Takeda Pharmaceutical Co Ltd - Nov 4, 2021 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
10%+ Owner
Signature
/s/ Amit Singh, Senior Vice President and Head of Treasury of Takeda Pharmaceutical Company Limited
Stock symbol
PHAT
Transactions as of
Nov 4, 2021
Transactions value $
-$20,850,019
Form type
4
Date filed
11/8/2021, 05:04 AM
Previous filing
Oct 26, 2021
Next filing
Nov 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Exercise of in-the-money or at-the-money derivative security $0 +229K +26.25% $0.00 1.1M Nov 4, 2021 Direct F1
transaction PHAT Common Stock Sale -$19 -1 0% $19.00 1.1M Nov 4, 2021 Direct F1
transaction PHAT Common Stock Sale -$20.9M -1M -90.91% $20.85 100K Nov 4, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Warrants Exercise of in-the-money or at-the-money derivative security $0 -229K -3.01% $0.00 7.36M Nov 4, 2021 Common Stock 229K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.